Kristel Tjandra is a science journalism intern at Drug Discovery News. She earned a PhD in chemistry from the University of New South Wales, Australia. Kristel is currently a postdoctoral scholar at Stanford University where she develops rapid diagnostics for multidrug-resistant bacteria. Her research focuses on therapeutics and diagnostics for cancer and infectious diseases. When not writing, she enjoys spending time outdoors playing tennis, cycling, and swimming.
Scientists found that the Kisspeptin hormone activates enzymes that stop lipid formation in the mouse liver, suggesting that it has potential as a drug target for treating non-alcoholic fatty liver disease.